Generalised pustular psoriasis is a rare and fatal neutrophilic skin ailment. Credit: Martin Trotter / Flickr (Creative Commons).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicine Agency (EMA) has recommended granting conditional marketing authorization (CMA) for Boehringer Ingelheim’s spesolimab as a therapy option in adults with generalised pustular psoriasis (GPP) flares. 

Based on the data from the Phase II EFFISAYIL 1 clinical trial of spesolimab in patients with GPP flares, the committee provided a positive opinion.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The 12-week trial analysed 900mg spesolimab administered intravenously versus a placebo.

After a week of treatment, 54% of patients in the spesolimab arm had no visible pustules versus 6% in the placebo arm.

Following 12 weeks, 84.4% of the subjects had no visible pustules while 81.3% had clear/almost clear skin.

See Also:

Additionally, adverse events were observed in 66% of subjects who received spesolimab versus 56% in the placebo arm after a week. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A new humanised, selective antibody, spesolimab hinders interleukin-36 receptor (IL-36R) activation. 

It is marketed as Spevigo in Japan and the US.

Apart from GPP flares, spesolimab is being analysed to treat other neutrophilic skin ailments.

Boehringer Ingelheim Human Pharma head Carinne Brouillon said: “This positive recommendation recognises spesolimab’s potential as a new targeted monoclonal antibody that could treat the underlying cause of GPP. 

“The accelerated development of spesolimab underscores our continued commitment to developing faster and more novel treatments for people with high unmet medical needs.”

A rare, heterogenous and fatal neutrophilic skin ailment, GPP is caused by the build-up of neutrophils in the skin.

The neutrophil accumulation leads to painful, sterile pustules in the body. 

In October last year, the EMA agreed to review the company’s marketing authorization application for spesolimab to treat GPP flares.